Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy [0.03%]
脆弱性不是ECOG：仅凭体能状态在抗癌治疗中已不再够用的原因
Waseem Jerjes
Waseem Jerjes
Optic glioma in children: clinical presentation, diagnosis, and management [0.03%]
儿童视神经胶质瘤的临床表现、诊断和治疗
Hilal Susam Sen,Ali Varan
Hilal Susam Sen
Introduction: Optic gliomas are slow-growing astrocytic tumors that frequently occur in children. The general treatment approach for optic gliomas should be based on tumor location, patient age, and NF1 status. Optic glio...
LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli health maintenance organization (HMO) [0.03%]
LUMINATE-101-Maccabi：一项真实世界研究，评估以色列健康维护组织中非鳞状细胞转移性非小细胞肺癌患者的治疗模式和临床结果
Sarah Sharman Moser,Alona Zer,Andre Hejazi et al.
Sarah Sharman Moser et al.
Background: Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1 L) therapy. This study evaluated real-world t...
177Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer [0.03%]
用于前列腺癌的177Lu-PSMA-617 放射配体治疗作为免疫调节疗法
Carolina Sciortino,Amedeo Nuzzo,Marco Stellato et al.
Carolina Sciortino et al.
Introduction: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge despite advances in systemic treatments. Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) w...
Artificial intelligence in retinoblastoma and uveal melanoma - a narrative review [0.03%]
人工智能在视网膜母细胞瘤和脉络膜黑色素瘤中的应用-综述文章
Bharat Gurnani,Kirandeep Kaur
Bharat Gurnani
Introduction: Artificial intelligence (AI) is reshaping diagnostic paradigms across oncology. In ophthalmic oncology encompassing conditions like retinoblastoma and uveal melanoma, AI has immense potential due to the spec...
Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region [0.03%]
免疫疗法在鼻咽癌中的作用：海湾合作委员会国家的临床和经济展望专家共识
Anas Hamad,Ahmed El-Sheashaey,Ahmed S Alanazi et al.
Anas Hamad et al.
Introduction: Nasopharyngeal carcinoma (NPC) is a rare malignancy globally but poses a disproportionate clinical and economic burden in endemic regions, including parts of the Gulf Cooperation Council (GCC). Patients with...
Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study [0.03%]
哈萨克斯坦定量和定性免疫法粪便潜血试验结直肠癌筛查对比研究
Abay Jumanov,Dilyara Kaidarova,Alma Zhylkaidarova et al.
Abay Jumanov et al.
Background: Late diagnosis of colorectal cancer (CRC) remains a public health challenge due to limitations in screening programs. This study evaluated the fecal immunochemical test (FIT) as an alternative screening method...
An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer [0.03%]
评估avutometinib联合defactinib治疗KRAS突变复发性低级别浆液性卵巢癌的效果
Vivek Podder,Brian M Slomovitz,Robert L Coleman
Vivek Podder
Introduction: Low-grade serous ovarian cancer (LGSOC) is a rare, biologically distinct subtype of epithelial ovarian cancer characterized by relative genomic stability, frequent activation of the mitogen-activated protein...
From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China [0.03%]
从预算限制到基于价值的支付：中国晚期三阴性乳腺癌使用萨西图珠单抗-替莫唑胺的增量成本效益分析
Shaohong Luo,Xiangzhen Wang,Lijing Yang et al.
Shaohong Luo et al.
Background: Robust pharmacoeconomic evidence regarding the long-term affordability of sacituzumab tirumotecan (sac-TMT) in treatment of metastatic triple-negative breast cancer (TNBC) remains lacking. We evaluated the cos...
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer [0.03%]
派姆单抗药物浓度监测及其与晚期非小细胞肺癌患者预后的关联研究
Ioannis P Trontzas,Anastasia Palaiologou,Natalia Kamperi et al.
Ioannis P Trontzas et al.
Background: Therapeutic drug monitoring (TDM) of immune checkpoint inhibitors (ICIs) remains limited due to drug-related challenges; however, a better understanding of exposure-effect relationships may improve antitumor a...